Onsolis filed in Canada

Onsolis filed in Canada 

The registration file for Onsolis (fentanyl buccal soluble film) has been
submitted to the Canadian regulatory authority; Health Canada. If approved, it
may become the first available fentanyl product approved for breakthrough pain
in opioid tolerant patients with cancer in Canada. A decision by Health Canada
is expected during 2010.

Canada represents an important market for Onsolis. The product will be
commercialized by the joint venture between Meda and Valeant (Meda Valeant
Pharma Canada Inc.). 

About Onsolis
Onsolis is a new and patented product, indicated for the management of
breakthrough pain in cancer patients who are tolerant to opioid therapy. Onsolis
uses a unique delivery system designed to give rapid and reliable delivery of
fentanyl. The product consists of a small dissolvable disc for application of
fentanyl to the buccal (inner lining of cheek) membranes. Onsolis has been
approved in the US and launch is expected to begin this month. In Europe,
Onsolis is under regulatory review with approval expected in 2010.

For more information, please contact:

Anders Larnholt, Vice President Investor Relations, tel. +46 709 458 878


MEDA AB (publ) is a leading international specialty pharma company. Meda's
products are sold in 120 countries worldwide and the company is represented by
its own organizations in more than 40 countries. The Meda share is listed under
Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more,
visit www.meda.se.